https://stanfordhealthcare.org/publications/827/827284.html
827284 | Stanford Health Care
The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results
stanfordhealthcare